Despite the company's success on the diagnostic front, Schoemaker was plunged in 1992 into efforts to save the company from bankruptcy when its first therapeutic, Centoxin, a drug designed to treat septic shock, failed to win FDA approval. In part the crisis had come about as a result of the company's executives trying to go it alone in developing the drug.
Despite the company's success in diagnostics, Schoemaker faced a crisis in 1992 when its first therapeutic, Centoxin, a drug designed to treat septic shock, failed FDA approval. This failure was partly due to the company's executives attempting to develop the drug independently.